Since the development of antibody-production techniques, a number of immunoglobulins
have been developed on a large scale using conventional methods. Hybridoma technology …

Recombinant antibody therapeutics represent a significant success story in terms of clinical
benefit delivered and revenue (profit) generated within the biopharmaceutical industry …

A prerequisite for the enrichment of antibodies screened from phage display libraries is their
stable expression on a phage during multiple selection rounds. Thus, if stringent panning …

Monoclonal antibodies are currently the most attractive therapeutic modality in a broad
range of disease areas, including infectious diseases, autoimmune diseases, and oncology …

As a natural function, antibodies defend the host from infected cells and pathogens by
recognizing their pathogenic determinants. Antibodies (Abs) gained wide acceptance with …

The production of the first therapeutic proteins in the early 1980s heralded the launch of the
biopharmaceuticals industry. The number of approved products has grown year on year …

Recent advances in combinatorial protein engineering have made it possible to develop
antibody-based and non-Ig protein scaffolds that can potentially substitute for most whole …

Solubility of recombinant proteins (ie, the extent of soluble versus insoluble expression in
heterogeneous hosts) is the first checkpoint criterion for determining recombinant protein …

Monoclonal antibodies (mAbs) are currently the largest and fastest growing class of
biopharmaceuticals, and they address unmet medical needs, eg, in oncology and in auto …

Antibody engineering has generally been carried out by displaying mouse or human
antibodies or antibody fragments on the surface of microorganisms (phage, bacteria, and …